Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/22/2025

Management of Orthostatic Hypotension with Midodrine

Pre-Treatment Requirements

  • The American Diabetes Association recommends confirming symptomatic orthostatic hypotension with a drop in systolic blood pressure of at least 15 mmHg from supine to standing position accompanied by symptoms, and attempting non-pharmacological measures such as volume repletion and discontinuation of offending medications before starting midodrine 1
  • The American Diabetes Association suggests excluding reversible causes of orthostatic hypotension, such as discontinuing or adjusting medications that exacerbate orthostatic hypotension, before starting midodrine 1
  • Correcting volume depletion by ensuring adequate hydration and considering salt supplementation is recommended before pharmacotherapy with midodrine 1

Initial Dosing Strategy

  • The American Diabetes Association recommends starting midodrine with a dose of 2.5-5 mg three times daily and titrating upward based on blood pressure response and symptom improvement 1
  • The initial dose of midodrine can be increased gradually to 10 mg three times daily if needed, based on standing blood pressure measured 1 hour post-dose, with peak blood pressure elevation occurring at 1 hour post-dose and duration of 2-4 hours 1

Special Population Adjustments

  • For hemodialysis patients, the American Journal of Kidney Diseases recommends using midodrine 5-10 mg administered 30 minutes before dialysis session, as midodrine is removed by dialysis 2
  • For patients with hepatorenal syndrome, the journal Hepatology suggests using a higher initial dose of midodrine 7.5 mg three times daily, titrated to 12.5 mg three times daily in combination with octreotide 3

Monitoring Requirements

  • The American Journal of Kidney Diseases recommends monitoring heart rate to watch for reflex bradycardia, particularly in patients on beta-blockers, digoxin, or non-dihydropyridine calcium channel blockers, when using midodrine 2
  • The American Diabetes Association suggests evaluating improvement in orthostatic symptoms within 1-2 weeks after initiating midodrine 1

Combination Therapy

  • The American Diabetes Association recommends adding fludrocortisone 0.05-0.3 mg daily for synergistic effect through sodium retention if midodrine monotherapy fails after titration to 10 mg three times daily 1

Midodrine Dosing and Administration for Orthostatic Hypotension

Titration and Administration

  • For orthostatic hypotension, treatment typically starts at lower doses and is titrated upward, with an initial dose of 2.5-5 mg three times daily, which can be gradually increased to 10 mg three times daily based on blood pressure response and symptom improvement, as recommended by the American Diabetes Association 4
  • For hepatorenal syndrome, midodrine should be initiated at 7.5 mg and titrated upward to 12.5 mg three times daily, in combination with octreotide, according to the American Gastroenterological Association 5, 6, 7

Special Populations

  • In hemodialysis patients, midodrine is removed by dialysis and may be used at doses of 5-10 mg to prevent intradialytic hypotension, as suggested by the National Kidney Foundation 8
  • Midodrine should be used cautiously in patients with heart failure and those taking other negative chronotropic agents such as beta-blockers, digoxin, and non-dihydropyridine calcium channel blockers, according to the American Journal of Kidney Diseases 8

Midodrine Dosing for Orthostatic Hypotension

Standard Dosing Parameters

  • The American Diabetes Association recommends a standard maximum dose of 10 mg three times daily for orthostatic hypotension, with careful monitoring for supine hypertension 9, 10

Evidence for Higher Dosing

  • The American Association for the Study of Liver Diseases suggests higher initial dosing of 7.5 mg TID, titrated to 12.5 mg TID, in combination with octreotide for hepatorenal syndrome 11, 12

Critical Safety Considerations

  • The American College of Cardiology recommends taking the final daily dose at least 4 hours before bedtime to reduce the risk of supine hypertension 9, 10
  • Supine hypertension is a primary dose-limiting adverse effect, occurring in 22% of patients at 10 mg doses and 45% of patients at 20 mg doses 9, 10

Practical Implementation

  • The American College of Cardiology suggests considering cardiology consultation given the off-label nature of 15 mg TID dosing 13
  • Monitoring for adverse effects, including supine hypertension, is crucial when increasing the dose to 15 mg TID 9, 10

REFERENCES